UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 17, 2020

Brainstorm Cell Therapeutics Inc.

(Exact name of registrant as specified in its charter)

(201) 488-0460

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

On November 17, 2020, Brainstorm Cell Therapeutics Inc. (the “Company”) issued a press release announcing Topline Results from its NurOwn^® Phase 3 ALS Study. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. 

The Company will host a conference call and live webcast at 8:30 am ET on Tuesday, November 17, 2020 to discuss the Topline Results from its NurOwn^® Phase 3 ALS Study. A live webcast of the conference call may be accessed by visiting the Investors & Media section of the Company’s website at http://www.ir.brainstorm-cell.com.

(d) Exhibits

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.